Texas § IN.1372.001 - DEFINITIONS

§ IN.1372.001. DEFINITIONS

DEFINITIONS. In this chapter: (1) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. The term includes: (A) gene mutations; and (B) protein expression. (2) "Biomarker testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. The term includes: (A) single-analyte tests; (B) multiplex panel tests; and (C) whole genome sequencing. (3) "Consensus statements" means statements that: (A) address specific clinical circumstances based on the best available evidence for the purpose of optimizing clinical care outcomes; and (B) are developed by an independent, multidisciplinary panel of experts that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy. (4) "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines that: (A) establish a standard of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options; (B) include recommendations intended to optimize patient care; and (C) are developed by an independent organization or medical professional society that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy. Added by Acts 2023, 88th Leg., R.S., Ch. 279 (S.B. 989 ), Sec. 1, eff. September 1, 2023.